Indolent lymphoma-why not to sprint at the start of a marathon
被引:0
|
作者:
Doucet, Stephane
论文数: 0引用数: 0
h-index: 0
机构:
Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USANorthwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
Doucet, Stephane
[1
,2
]
Gordon, Leo I.
论文数: 0引用数: 0
h-index: 0
机构:
Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USANorthwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
Gordon, Leo I.
[1
,2
]
机构:
[1] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
A new study has shown that rituximab and bendamustine provide better outcomes and less toxicity than rituximab plus CHOP chemotherapy in patients with indolent lymphomas. However, whether this represents a practice-changing development is unclear and we should not rush to judgement without answering some key questions.
机构:
Ajou Univ, Dept Hematol Oncol, Sch Med, 164 World Cup Ro, Suwon 16499, South KoreaAjou Univ, Dept Hematol Oncol, Sch Med, 164 World Cup Ro, Suwon 16499, South Korea
机构:
Univ Penn, Sch Med, Dept Med, Med Intens Care Unit,Penn Presbyterian Med Ctr, Philadelphia, PA 19104 USA
Univ Penn, Sch Med, Ctr Resuscitat Sci, Philadelphia, PA 19104 USAUniv Penn, Sch Med, Dept Med, Med Intens Care Unit,Penn Presbyterian Med Ctr, Philadelphia, PA 19104 USA
Bhardwaj, Abhishek
Mikkelsen, Mark E.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Penn, Dept Med, Perelman Sch Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA
Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USAUniv Penn, Sch Med, Dept Med, Med Intens Care Unit,Penn Presbyterian Med Ctr, Philadelphia, PA 19104 USA